Biotest AG
XETRA:BIO2

Watchlist Manager
Biotest AG Logo
Biotest AG
XETRA:BIO2
Watchlist
Price: 43.02 EUR Market Closed
Market Cap: 1.7B EUR

Operating Margin
Biotest AG

1.9%
Current
5%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
1.9%
=
Operating Profit
11.9m
/
Revenue
635.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DE
Biotest AG
XETRA:BIO
1.6B EUR
2%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
400.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD
28%
AU
CSL Ltd
ASX:CSL
84.8B AUD
26%
NL
argenx SE
XBRU:ARGX
45B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
No Stocks Found

Biotest AG
Glance View

Market Cap
1.7B EUR
Industry
Biotechnology

Biotest AG, headquartered in Dreieich, Germany, is a pivotal player in the field of biopharmaceuticals, with a particular focus on blood plasma-derived products. The company traces its origins back to 1946 when it was founded as a laboratory for blood testing, and since then, it has transformed into a significant force in the healthcare sector. Biotest operates on a vertically integrated business model, from collecting plasma to the manufacturing and distribution of therapeutic proteins. The company primarily produces and markets products like immunoglobulins, coagulation factors, and albumins, which are essential for treating immune system deficiencies, blood clotting disorders, and various other ailments. These products serve not only to improve the quality of life for patients but are critical lifelines for those with chronic and acute conditions. Revenue generation at Biotest revolves around a three-pronged strategy: plasma collection, manufacturing, and commercialization of its proprietary therapies. The process begins with the acquisition of raw plasma through an extensive network of collection centers. This plasma is then processed and transformed into high-value therapeutic products in sophisticated manufacturing facilities. Biotest’s revenue stream is bolstered by its strong presence in international markets, serving hospitals, clinics, and healthcare systems with high demand for its specialized products. By leveraging its in-depth expertise in plasma technology and robust infrastructure, Biotest AG has carved a niche, ensuring a steady flow of returns while contributing significantly to advancements in treating rare diseases and fostering global health betterment.

BIO2 Intrinsic Value
33.92 EUR
Overvaluation 21%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
1.9%
=
Operating Profit
11.9m
/
Revenue
635.2m
What is the Operating Margin of Biotest AG?

Based on Biotest AG's most recent financial statements, the company has Operating Margin of 1.9%.

Back to Top